Purinergic signaling and energy homeostasis in psychiatric disorders

Current Molecular Medicine

Volumn 15, Issue 3, 2015, Pages 275-295

  Lindberg, D ^a   Shan, D ^b   Ayers Ringler, J ^c   Oliveros, A ^d   Benitez, J ^d   Prieto, M ^e,f   McCullumsmith, R ^g   Choi, D S ^c,d,e  

^a Mayo Clinic MD PhD Program   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Neurobiology of Disease Program   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e Mayo Clinic College of Medicine   (United States)

^f UNIVERSIDAD DE LOS ANDES   (Chile)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adenosine; ATP; Energy homeostasis; Glutamate; Mental disorders; Mitochondria; Purine

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; CALCIUM; CLOZAPINE; DIPYRIDAMOLE; IMIPRAMINE; PROPENTOFYLLINE; GLUTAMIC ACID; PURINERGIC RECEPTOR;

ADDICTION; ARTICLE; AUTISM; BIPOLAR DISORDER; CELL INTERACTION; CLINICAL TRIAL (TOPIC); DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY BALANCE; GENETIC VARIABILITY; GLIA; HOMEOSTASIS; HUMAN; KETOGENIC DIET; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL PLASTICITY; NERVE FIBER; NERVE FIBER TRANSPORT; NERVOUS SYSTEM FUNCTION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PURINERGIC SIGNALING; RETROGRADE NERVE FIBER TRANSPORT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; ENERGY METABOLISM; METABOLISM; SYNAPSE; SYNAPTIC TRANSMISSION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; ENERGY METABOLISM; GLUTAMIC ACID; HOMEOSTASIS; HUMANS; MENTAL DISORDERS; NEURONAL PLASTICITY; RECEPTORS, PURINERGIC; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84929616952     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150330163724     Document Type: Article

References (222)

1. [1] Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 2008;7:575-90.
2. [2] Patti L, Raiteri L, Grilli M, et al. P2X(7) receptors exert a permissive role on the activation of release-enhancing presynaptic alpha7 nicotinic receptors co-existing on rat neocortex glutamatergic terminals. Neuropharmacology 2006;50:705-13.
3. [3] Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, Cunha RA. Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J Neurosci 2005;25:6286-95.
4. [4] Barraco RA, Martens KA, Parizon M, Normile HJ. Adenosine A2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 1993;31:397-404.
5. [5] Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol 2004;73:379-96.
6. [6] Deheshi S, Pasqualotto BA, Rintoul GL. Mitochondrial trafficking in neuropsychiatric diseases. Neurobiol Dis 2013;51:66-71.
7. [7] MacAskill AF, Atkin TA, Kittler JT. Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses. Euro J Neurosci 2010;32:231-40.
8. [8] MacAskill AF, Kittler JT. Control of mitochondrial transport and localization in neurons. Trends Cell Biol 2010;20:102-12.
9. [9] Itoh K, Nakamura K, Iijima M, Sesaki H. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol 2013;23:64-71.
10. [10] Zhu J, Wang KZ, Chu CT. After the banquet: mitochondrial biogenesis, mitophagy, and cell survival. Autophagy 2013;9:1663-76.
11. [11] Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci 2005;118:5411-9.
12. [12] Mironov SL. ADP regulates movements of mitochondria in neurons. Biophy J 2007;92:2944-52.
13. [13] Hendricks AG, Perlson E, Ross JL, et al. Motor coordination via a tug-of-war mechanism drives bidirectional vesicle transport. Curr Biol 2010;20:697-702.
14. [14] Ligon LA, Steward O. Movement of mitochondria in the axons and dendrites of cultured hippocampal neurons. J Comp Neurol 2000;427:340-50.
15. [15] Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004;119:873-87.
16. [16] Saxton WM, Hollenbeck PJ. The axonal transport of mitochondria. J Cell Sci 2012;125:2095-104.
17. [17] Amiri M, Hollenbeck PJ. Mitochondrial biogenesis in the axons of vertebrate peripheral neurons. Devel Neurobiol 2008;68:1348-61.
18. [18] Manji H, Kato T, Di Prospero NA, et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012;13:293-307.
19. [19] Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002;80:780-7.
20. [20] Jiao S, Li Z. Nonapoptotic Function of BAD and BAX in Long-Term Depression of Synaptic Transmission. Neuron 2011;70:758-72.
21. [21] Li Z, Jo J, Jia JM, et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010;141:859-71.
22. [22] Burnstock G. Purinergic Signalling in the CNS. Open Neuroscience Journal 2010;4:24-30.
23. [23] Burnstock G. Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future. BioEssays 2012;34:218-25.
24. [24] Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. ASN Neuro 2010;2:e00045.
25. [25] Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008;60:748-66.
26. [26] Chen S, Owens GC, Edelman DB. Dopamine inhibits mitochondrial motility in hippocampal neurons. PLoS One 2008;3:e2804.
27. [27] Macaskill AF, Rinholm JE, Twelvetrees AE, et al. Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron 2009;61:541-55.
28. [28] Chang DT, Honick AS, Reynolds IJ. Mitochondrial trafficking to synapses in cultured primary cortical neurons. J Neurosci 2006;26:7035-45.
29. [29] Schinder AF, Olson EC, Spitzer NC, Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996;16:6125-33.
30. [30] Brenner-Lavie H, Klein E, Ben-Shachar D. Mitochondrial complex I as a novel target for intraneuronal DA: modulation of respiration in intact cells. Biochem Pharmacol 2009;78:85-95.
31. [31] Brenner-Lavie H, Klein E, Zuk R, et al. Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochim BiophyActa 2008;1777:173-85.
32. [32] Krugel U, Kittner H, Franke H, Illes P. Purinergic modulation of neuronal activity in the mesolimbic dopaminergic system in vivo. Synapse 2003;47:134-42.
33. [33] Choi DS, Cascini MG, Mailliard W, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004;7:855-61.
34. [34] Naassila M, Ledent C, Daoust M. Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. J Neurosci 2002;22:10487-93.
35. [35] Nam HW, Hinton DJ, Kang NY, et al. Adenosine transporter ENT1 regulates the acquisition of goal-directed behavior and ethanol drinking through A2A receptor in the dorsomedial striatum. J Neurosci 2013;33:4329-38.
36. [36] Burnstock G. Purinergic nerves. Pharmacol Rev 1972;24:509-81.
37. [37] Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007;87:659-797.
38. [38] Mori M, Heuss C, Gahwiler BH, Gerber U. Fast synaptic transmission mediated by P2X receptors in CA3 pyramidal cells of rat hippocampal slice cultures. J Physiol 2001;535:115-23.
39. [39] Jo YH, Role LW. Coordinate release of ATP and GABA at in vitro synapses of lateral hypothalamic neurons. J Neurosci 2002;22:4794-804.
40. [40] Poelchen W, Sieler D, Wirkner K, Illes P. Co-transmitter function of ATP in central catecholaminergic neurons of the rat. Neurosci 2001;102:593-602.
41. [41] Zimmermann H. ATP and acetylcholine, equal brethren. Neurochem Intl 2008;52:634-48.
42. [42] Hassinger TD, Guthrie PB, Atkinson PB, Bennett MV, Kater SB. An extracellular signaling component in propagation of astrocytic calcium waves. PNAS 1996;93:13268-73.
43. [43] Wang Z, Haydon PG, Yeung ES. Direct observation of calcium-independent intercellular ATP signaling in astrocytes. Anal Chem 2000;72:2001-7.
44. [44] Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci 2009;32:19-29.
45. [45] van Calker D, Muller M, Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 1979;33:999-1005.
46. [46] Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 1994;371:519-23.
47. [47] Nam HW, McIver SR, Hinton DJ, et al. Adenosine and glutamate signaling in neuron-glial interactions: implications in alcoholism and sleep disorders. Alcohol Clin Exp Ther 2012;36:1117-25.
48. [48] Palmer TM, Benovic JL, Stiles GL. Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinasemediated mechanism. J Biol Chem 1995;270:29607-13.
49. [49] Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012;8:437-502.
50. [50] Durieux J, Wolff S, Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 2011;144:79-91.
51. [51] Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 1985;16:433-40.
52. [52] Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Intl Rev Cytology 2004;240:31-304.
53. [53] Naviaux RK. Metabolic features of the cell danger response. Mitochondrion 2014;16:7-17.
54. [54] Chen Y, Yao Y, Sumi Y, et al. Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci Signaling 2010;3:ra45.
55. [55] Harada K, Hide I, Seki T, et al. Extracellular ATP differentially modulates Toll-like receptor 4-mediated cell survival and death of microglia. J Neurochem 2011;116:1138-47.
56. [56] Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011;11:201-12.
57. [57] Di Virgilio F, Ceruti S, Bramanti P, Abbracchio MP. Purinergic signalling in inflammation of the central nervous system. Trends Neurosci 2009;32:79-87.
58. [58] Arakawa S, Shirayama Y, Fujita Y, et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behv 2012;100:601-6.
59. [59] Hinwood M, Tynan RJ, Charnley JL, et al., Chronic stress induced remodeling of the prefrontal cortex: structural reorganization of microglia and the inhibitory effect of minocycline. Cerebral Cortex 2013;23:1784-97.
60. [60] Wohleb ES, Hanke ML, Corona AW, et al. beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci 2011;31:6277-88.
61. [61] Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatric Res 2008;42:151-7.
62. [62] Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflamm 2011;8:94.
63. [63] McQuillin A, Bass NJ, Choudhury K, et al. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar-and unipolaraffective disorders. Mol Psychiatry 2009;14:614-20.
64. [64] Nagy G, Ronai Z, Somogyi A, et al. P2RX7 Gln460Arg polymorphism is associated with depression among diabetic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1884-8.
65. [65] Basso AM, Bratcher NA, Harris RR, et al. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behv Brain Res 2009;198:83-90.
66. [66] Hamilton N, Vayro S, Kirchhoff F, et al. Mechanisms of ATPand glutamate-mediated calcium signaling in white matter astrocytes. Glia 2008;56:734-49.
67. [67] Kreft M, Potokar M, Stenovec M, Pangrsic T, Zorec R. Regulated exocytosis and vesicle trafficking in astrocytes. Annals NYAcad Sci 2009;1152:30-42.
68. [68] Pangrsic T, Potokar M, Stenovec M, et al. Exocytotic release of ATP from cultured astrocytes. J Biol Chem 2007;282:28749-58.
69. [69] Jourdain P, Bergersen LH, Bhaukaurally K, et al. Glutamate exocytosis from astrocytes controls synaptic strength. Nat Neurosci 2007;10:331-9.
70. [70] Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. PNAS 2012;109:E197-205.
71. [71] Zeng JW, Liu XH, Zhang JH, Wu XG, Ruan HZ. P2Y1 receptor-mediated glutamate release from cultured dorsal spinal cord astrocytes. J Neurochem 2008;106:2106-18.
72. [72] Vavra V, Bhattacharya A, Zemkova H. Facilitation of glutamate and GABA release by P2X receptor activation in supraoptic neurons from freshly isolated rat brain slices. Neurosci 2011;188:1-12.
73. [73] Pankratov Y, Lalo U, Krishtal OA, Verkhratsky A. P2X receptors and synaptic plasticity. Neurosci 2009;158:137-48.
74. [74] Pankratov YV, Lalo UV, Krishtal OA. Role for P2X receptors in long-term potentiation. J Neurosci 2002;22:8363-9.
75. [75] Stobart JL, Anderson CM. Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front Cell Neurosci 2013;7:38.
76. [76] Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. PNAS 1994;91:10625-9.
77. [77] Hertz L, Peng L, Dienel GA. Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J Cereb Blood Flow Metabolism 2007;27:219-49.
78. [78] O'Dowd BS, Gibbs ME, Sedman GL, Ng KT. Astrocytes implicated in the energizing of intermediate memory processes in neonate chicks. Brain Res Cogn Brain Res 1994;2:93-102.
79. [79] Genda EN, Jackson JG, Sheldon AL, et al. Cocompartmentalization of the astroglial glutamate transporter, GLT-1, with glycolytic enzymes and mitochondria. J Neurosci 2011;31:18275-88.
80. [80] Pascual O, Casper KB, Kubera C, et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005;310:113-6.
81. [81] Matos M, Augusto E, Agostinho P, Cunha RA, Chen JF. Antagonistic interaction between adenosine A2A receptors and Na+/K+-ATPase-alpha2 controlling glutamate uptake in astrocytes. J Neurosci 2013;33:18492-502.
82. [82] Nishizaki T. ATP-and adenosine-mediated signaling in the central nervous system: adenosine stimulates glutamate release from astrocytes via A2a adenosine receptors. J Pharmacol Sci 2004;94:100-2.
83. [83] Duan W, Gui L, Zhou Z, et al. Adenosine A2A receptor deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral hypoperfusion in mice. J Neurol Sci 2009;285:39-45.
84. [84] Mievis S, Blum D, Ledent C. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2011;41:570-6.
85. [85] Canas PM, Porciuncula LO, Cunha GM, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009;29:14741-51.
86. [86] Bailey A, Davis L, Lesscher HM, et al. Enhanced morphine withdrawal and micro-opioid receptor G-protein coupling in A2A adenosine receptor knockout mice. J Neurochem 2004;88:827-34.
87. [87] Castane A, Soria G, Ledent C, Maldonado R, Valverde O. Attenuation of nicotine-induced rewarding effects in A2A knockout mice. Neuropharmacology 2006;51:631-40.
88. [88] Soria G, Castane A, Berrendero F, et al. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci 2004;20:2203-13.
89. [89] Soria G, Castane A, Ledent C, et al. The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacol 2006;31:978-87.
90. [90] Le KT, Babinski K, Seguela P. Central P2X4 and P2X6 channel subunits coassemble into a novel heteromeric ATP receptor. J Neurosci 1998;18:7152-9.
91. [91] Ciruela F, Ferre S, Casado V, et al. Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cell Mol Life Sci 2006;63:2427-31.
92. [92] Gines S, Hillion J, Torvinen M, et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. PNAS 2000;97:8606-11.
93. [93] Hillion J, Canals M, Torvinen M, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002;277:18091-7.
94. [94] Cabello N, Gandia J, Bertarelli DC, et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 2009;109:1497-507.
95. [95] Carriba P, Ortiz O, Patkar K, et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacol 2007;32:2249-59.
96. [96] Ferre S, Lluis C, Justinova Z, et al. Adenosine-cannabinoid receptor interactions. Implications for striatal function. Brit J Pharmacol 2010;160:443-53.
97. [97] Yao L, McFarland K, Fan P, et al. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. PNAS 2006;103:7877-82.
98. [98] Peng L, Huang R, Yu AC, et al. Nucleoside transporter expression and function in cultured mouse astrocytes. Glia 2005;52:25-35.
99. [99] Wu J, Lee MR, Choi S, Kim T, Choi DS. ENT1 regulates ethanol-sensitive EAAT2 expression and function in astrocytes. Alcohol Clin Exp Res 2010;34:1110-7.
100. [100] Bennett MR. Synaptic P2X7 receptor regenerative-loop hypothesis for depression. The Australian New Zealand J Psychiatry 2007;41:563-71.
101. [101] Lai AY, Swayze RD, El-Husseini A, Song C. Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J Neuroimmunol 2006;175:97-106.
102. [102] Tanabe K, Nishimura K, Dohi S, Kozawa O. Mechanisms of interleukin-1beta-induced GDNF release from rat glioma cells. Brain Res 2009;1274:11-20.
103. [103] Cao X, Li LP, Wang Q, et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med 2013;19:773-7.
104. [104] Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nature reviews Neuroscience 2006;7:423-36.
105. [105] Bodin P, Burnstock G. Evidence that release of adenosine triphosphate from endothelial cells during increased shear stress is vesicular. J Cardiovascular Pharmacol 2001;38:900-8.
106. [106] Nam HW, Lee MR, Zhu Y, et al. Type 1 equilibrative nucleoside transporter regulates ethanol drinking through accumbal N-methyl-D-aspartate receptor signaling. Biol Psychiatry 2011;69:1043-51.
107. [107] Blondeau N, Plamondon H, Richelme C, Heurteaux C, Lazdunski M. K(ATP) channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal neuroprotection. Neurosci 2000;100:465-74.
108. [108] Joseph EK, Levine JD. Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 2006;121:105-14.
109. [109] Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006;314:1792-5.
110. [110] Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104-7.
111. [111] Amadio S, D'Ambrosi N, Trincavelli ML, et al. Differences in the neurotoxicity profile induced by ATP and ATPgammaS in cultured cerebellar granule neurons. Neurochem Intl 2005;47:334-42.
112. [112] Deli T, Csernoch L. Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol Oncology Res 2008;14:219-31.
113. [113] Inoue K, Tsuda M, Tozaki-Saitoh H. Modification of neuropathic pain sensation through microglial ATP receptors. Purinergic Signaling 2007;3:311-6.
114. [114] Barsotti C, Ipata PL. Metabolic regulation of ATP breakdown and of adenosine production in rat brain extracts. Intl J Biochem and Cell Biol 2004;36:2214-25.
115. [115] Jha MK, Jeon S, Suk K. Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronalglial Metabolic Interaction and Neuro-metabolic Disorders. Curr Neuropharmacol 2012;10:393-403.
116. [116] Butterworth RF. Altered glial-neuronal crosstalk: cornerstone in the pathogenesis of hepatic encephalopathy. Neurochem Intl 2010;57:383-8.
117. [117] Lu H, Burns D, Garnier P, et al. P2X7 receptors mediate NADH transport across the plasma membranes of astrocytes. Biochem Biophys Res Commun 2007;362:946-50.
118. [118] Alano CC, Garnier P, Ying W, et al. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010;30:2967-78.
119. [119] Masino SA, Geiger JD. Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets? Trends Neurosci 2008;31:273-8.
120. [120] Wilder RM. Recollections and reflections on education, diabetes, other metabolic diseases, and nutrition in the Mayo Clinic and associated hospitals, 1919-50. Perspectives Biol Med 1958;1:237-77.
121. [121] Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Annals Neurol 2006;60:223-35.
122. [122] Andoh T, Ishiwa D, Kamiya Y, et al. A1 adenosine receptormediated modulation of neuronal ATP-sensitive K channels in rat substantia nigra. Brain Res 2006;1124:55-61.
123. [123] Shen HY, Singer P, Lytle N, et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J Clin Invest 2012;122:2567-77.
124. [124] Singer P, Wei CJ, Chen JF, Boison D, Yee BK. Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning. Behv Brain Res 2013;242:54-61.
125. [125] Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008;321:848-51.
126. [126] Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006;29:647-54.
127. [127] Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem 2013;127:552-61.
128. [128] Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-51.
129. [129] Post RM, Leverich GS, Kupka RW, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clinical Psychiatry 2010;71:864-72.
130. [130] Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-50.
131. [131] McMahon FJ, Stine OC, Meyers DA, Simpson SG, DePaulo JR. Patterns of maternal transmission in bipolar affective disorder. Am J Hum Gen 1995;56:1277-86.
132. [132] Munakata K, Iwamoto K, Bundo M, Kato T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry 2005;57:525-32.
133. [133] Rollins B, Martin MV, Sequeira PA, et al. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS One 2009;4:e4913.
134. [134] Kazuno AA, Munakata K, Mori K, et al. Mitochondrial DNA haplogroup analysis in patients with bipolar disorder. Am Med Genetics 2009;150B:243-7.
135. [135] Kato T, Stine OC, McMahon FJ, Crowe RR. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol Psychiatry 1997;42:871-5.
136. [136] Kakiuchi C, Ishiwata M, Kametani M, et al. Quantitative analysis of mitochondrial DNA deletions in the brains of patients with bipolar disorder and schizophrenia. Intl J Neuropsychopharmacol 2005;8:515-22.
137. [137] Torrell H, Montana E, Abasolo N, et al. Mitochondrial DNA (mtDNA) in brain samples from patients with major psychiatric disorders: gene expression profiles, mtDNA content and presence of the mtDNA common deletion. Am Med Genetics 2013;162B:213-23.
138. [138] Siciliano G, Tessa A, Petrini S, et al. Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscular Dis 2003;13:162-5.
139. [139] Chen H, Wang N, Zhao X, et al. Gene expression alterations in bipolar disorder postmortem brains. Bipolar Dis 2013;15:177-87.
140. [140] Dubovsky SL, Murphy J, Thomas M, Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 1992;149:118-20.
141. [141] Emamghoreishi M, Schlichter L, Li PP, et al. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry 1997;154:976-82.
142. [142] Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011;43:977-83.
143. [143] Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67:360-8.
144. [144] Gubert C, Stertz L, Pfaffenseller B, et al. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J Psychiatric Res 2013;47:1396-402.
145. [145] Naydenov AV, MacDonald ML, Ongur D, Konradi C. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry 2007;64:555-64.
146. [146] Cataldo AM, McPhie DL, Lange NT, et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 2010;177:575-85.
147. [147] Kato T, Murashita J, Kamiya A, et al. Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clinical Neurosci1998;248:301-6.
148. [148] Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004;61:450-8.
149. [149] Kato T, Takahashi S, Shioiri T, et al. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Dis 1994;31:125-33.
150. [150] Deicken RF, Fein G, Weiner MW. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry 1995;152:915-8.
151. [151] Kasahara T, Kubota M, Miyauchi T, et al. Mice with neuronspecific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry 2006;11:577-93, 23.
152. [152] Kubota M, Kasahara T, Iwamoto K, et al. Therapeutic implications of down-regulation of cyclophilin D in bipolar disorder. Intl J Neuropsychopharmacol 2010;13:1355-68.
153. [153] Moretti M, Valvassori SS, Steckert AV, et al. Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacol Biochem Behv 2011;98:304-10.
154. [154] Jornada LK, Valvassori SS, Steckert AV, et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatric Res 2011;45:162-8.
155. [155] Valvassori SS, Rezin GT, Ferreira CL, et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatric Res 2010;44:903-9.
156. [156] Toker L, Bersudsky Y, Plaschkes I, et al. Inositol-Related Gene Knockouts Mimic Lithium's Effect on Mitochondrial Function. Neuropsychopharmacol 2014;39:319-28.
157. [157] De Berardis D, Conti CM, Campanella D, et al. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J Biol Regul Homeostat Agents s 2008;22:195-200.
158. [158] Salvadore G, Viale CI, Luckenbaugh DA, et al. Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode. Prog Neuro-psychopharmacol Biol Psychiatry 2010;34:819-21.
159. [159] Hirota T, Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schiz Res 2013;149:88-95.
160. [160] Backlund L, Nikamo P, Hukic DS, et al. Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar Dis 2011;13:500-8.
161. [161] Soronen P, Mantere O, Melartin T, et al. P2RX7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts. Am J Med Genetics 2011;156B:435-47.
162. [162] Grigoroiu-Serbanescu M, Herms S, Muhleisen TW, et al. Variation in P2RX7 candidate gene (rs2230912) is not associated with bipolar I disorder and unipolar major depression in four European samples. Am J Med Genetics 2009;150B:1017-21.
163. [163] DeLisi LE, Razi K, Stewart J, et al. No evidence for a parentof-origin effect detected in the pattern of inheritance of schizophrenia. Biol Psychiatry 2000;48:706-9.
164. [164] Verge B, Alonso Y, Miralles C, et al. New evidence for the involvement of mitochondrial inheritance in schizophrenia: results from a cross-sectional study evaluating the risk of illness in relatives of schizophrenia patients. J Clin Psychiatry 2012;73:684-90.
165. [165] Ma L, Zhang W, Tang J, et al. No association between genetic polymorphisms of the NDUFS7 gene and schizophrenia in Han Chinese. Psychiatr Genet 2013;23:29-32.
166. [166] Mosquera-Miguel A, Torrell H, Abasolo N, et al. No evidence that major mtDNA European haplogroups confer risk to schizophrenia. Am J Med Genetics 2012;159B:414-21.
167. [167] Crombie C, Walsh DA, Lu W, et al. Electrically-controlled rapid femtosecond pulse duration switching and continuous picosecond pulse duration tuning in an ultrafast Cr4+:forsterite laser. Optics Express 2012;20:18138-44.
168. [168] Millar JK, James R, Christie S, Porteous DJ. Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria. Mol Cell Neurosci 2005;30:477-84.
169. [169] Atkin TA, Brandon NJ, Kittler JT. Disrupted in Schizophrenia 1 forms pathological aggresomes that disrupt its function in intracellular transport. Hum Mol Genetics 2012;21:2017-28.
170. [170] Washizuka S, Kametani M, Sasaki T, et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with schizophrenia in the Japanese population. Am J Med Genetics 2006;141B:301-4.
171. [171] Gigante AD, Andreazza AC, Lafer B, et al. Decreased mRNA expression of uncoupling protein 2, a mitochondrial proton transporter, in post-mortem prefrontal cortex from patients with bipolar disorder and schizophrenia. Neurosci Lett 2011;505:47-51.
172. [172] Washizuka S, Iwamoto K, Kakiuchi C, Bundo M, Kato T. Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neurosci Res 2009;63:199-204.
173. [173] Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schiz Bull 2009;35:549-62.
174. [174] Nieratschker V, Nothen MM, Rietschel M. New Genetic Findings in Schizophrenia: Is there Still Room for the Dopamine Hypothesis of Schizophrenia? Front Behavioral Neurosci 2010;4:23.
175. [175] Javitt DC. Glutamate and schizophrenia: phencyclidine, Nmethyl-D-aspartate receptors, and dopamine-glutamate interactions. Intl Rev Neurobiol 2007;78:69-108.
176. [176] Avshalumov MV, Rice ME. Activation of ATP-sensitive K+ (K(ATP)) channels by H2O2 underlies glutamate-dependent inhibition of striatal dopamine release. PNAS 2003;100:11729-34.
177. [177] Dean O, Bush AI, Berk M, Copolov DL, van den Buuse M. Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacol Biochem Behv 2010;97:293-300.
178. [178] Corena-McLeod M, Walss-Bass C, Oliveros A, et al. New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations. PLoS One 2013;8:e52147.
179. [179] Corena-McLeod Mdel P, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008;1233:8-19.
180. [180] de Oliveira L, Fraga DB, De Luca RD, et al. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab Brain Dis 2011;26:69-77.
181. [181] Moller M, Du Preez JL, Viljoen FP, et al. Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behv Immunity 2013;30:156-67.
182. [182] Oliveros A, Heckman MG, Del Pilar Corena-McLeod M, et al. Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine, clozapine and NT69L. J Exp Biol 2010;213:4232-9.
183. [183] Zugno AI, Chipindo HL, Volpato AM, et al. Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neurosci 2014;259:223-31.
184. [184] Wang JH, Short J, Ledent C, Lawrence AJ, van den Buuse M. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behv Brain Res 2003;143:201-7.
185. [185] Zhang J, Abdallah CG, Wang J, et al. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Res 2012;200:126-32.
186. [186] Deicken RF, Calabrese G, Merrin EL, et al. Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: a 31phosphorous magnetic resonance spectroscopic imaging study. Biol Psychiatry 1995;38:279-86.
187. [187] Shirayama Y, Yano T, Takahashi K, Takahashi S, Ogino T. In vivo 31P NMR spectroscopy shows an increase in glycerophosphorylcholine concentration without alterations in mitochondrial function in the prefrontal cortex of medicated schizophrenic patients at rest. Eur J Neurosci 2004;20:749-56.
188. [188] Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 2012;37:2635-42.
189. [189] Gotoh L, Mitsuyasu H, Kobayashi Y, et al. Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population. Psychiatr Genet 2009;19:328-35.
190. [190] Deckert J, Nothen MM, Rietschel M, et al. Human adenosine A2a receptor (A2aAR) gene: systematic mutation screening in patients with schizophrenia. J Neural Transm 1996;103:1447-55.
191. [191] Hong CJ, Liu HC, Liu TY, Liao DL, Tsai SJ. Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. J Neural Transm 2005;112:1503-10.
192. [192] Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012;17:389-401.
193. [193] Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. JAMA 2010;304:2389-96.
194. [194] Chauhan A, Gu F, Essa MM, et al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 2011;117:209-20.
195. [195] Tang G, Gutierrez Rios P, Kuo SH, et al. Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis 2013;54:349-61.
196. [196] James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 2009;23:2374-83.
197. [197] Kent L, Gallagher L, Elliott HR, Mowbray C, Chinnery PF. An investigation of mitochondrial haplogroups in autism. Am J Med Genet 2008;147B:987-9.
198. [198] Chugani DC, Sundram BS, Behen M, Lee ML, Moore GJ. Evidence of altered energy metabolism in autistic children. Prog Neuro-psychopharmacol Biol Psychiatry 1999;23:635-41.
199. [199] Corrigan NM, Shaw DW, Richards TL, et al. Proton magnetic resonance spectroscopy and MRI reveal no evidence for brain mitochondrial dysfunction in children with autism spectrum disorder. J Autism Devel Dis 2012;42:105-15.
200. [200] Persico AM, Militerni R, Bravaccio C, et al. Adenosine deaminase alleles and autistic disorder: case-control and family-based association studies. Am J Med Genet 2000;96:784-90.
201. [201] Freitag CM, Agelopoulos K, Huy E, et al. Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder. Eur Child Adolesc Psychiatry 2010;19:67-74.
202. [202] Campbell NG, Zhu CB, Lindler KM, et al. Rare coding variants of the adenosine A3 receptor are increased in autism: on the trail of the serotonin transporter regulome. Mol Autism 2013;4:28.
203. [203] Naviaux RK, Zolkipli Z, Wang L, et al. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. PLoS One 2013;8:e57380.
204. [204] Bolton PF, Griffiths PD. Association of tuberous sclerosis of temporal lobes with autism and atypical autism. Lancet 1997;349:392-5.
205. [205] Di Nardo A, Kramvis I, Cho N, et al. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J Neurosci 2009;29:5926-37.
206. [206] Wyatt LR, Godar SC, Khoja S, et al. Sociocommunicative and sensorimotor impairments in male P2X4-deficient mice. Neuropsychopharmacology 2013;38:1993-2002.
207. [207] Bergemann ER, Boles RG. Maternal inheritance in recurrent early-onset depression. Psychiatr Genet 2010;20:31-4.
208. [208] Kim GH, Jeon S, Seo SW, et al. Topography of cortical thinning areas associated with hippocampal atrophy (HA) in patients with Alzheimer's disease (AD). Arch Gerontol Geriatr 2012;54:e122-9.
209. [209] Chen F, Wegener G, Madsen TM, Nyengaard JR. Mitochondrial plasticity of the hippocampus in a genetic rat model of depression after antidepressant treatment. Synapse 2013;67:127-34.
210. [210] Gardner A, Johansson A, Wibom R, et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Dis 2003;76:55-68.
211. [211] Maeng S, Hunsberger JG, Pearson B, et al. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. PNAS 2008;105:8766-71.
212. [212] Silva R, Mesquita AR, Bessa J, et al. Lithium blocks stressinduced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008;152:656-69.
213. [213] Huang YY, Peng CH, Yang YP, et al. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 2007;104:61-72.
214. [214] Kosten TA, Galloway MP, Duman RS, Russell DS, D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008;33:1545-58.
215. [215] Murray F, Hutson PH. Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur J Pharmacol 2007;569:41-7.
216. [216] Malkesman O, Austin DR, Tragon T, et al. Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol Psychiatry 2012;17:770-80.
217. [217] Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997;154:116-8.
218. [218] Berk M, Plein H, Ferreira D, Jersky B. Blunted adenosine A2a receptor function in platelets in patients with major depression. Eur Neuropsychopharmacol 2001;11:183-6.
219. [219] Viikki M, Kampman O, Anttila S, et al. P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. Neurosci Lett 2011;493:127-30.
220. [220] Halmai Z, Dome P, Vereczkei A, et al. Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms. J Affect Dis 2013;150:104-9.
221. [221] Boucher AA, Arnold JC, Hunt GE, et al. Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 2011;189:170-7.
222. [222] Gershon ES, Alliey-Rodriguez N, Liu C. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry 2011;168:253-6.